University of Massachusetts Amherst researchers reported a nanoparticle vaccine that combines cancer‑specific antigens with a multi‑pathway 'super' adjuvant to prevent tumor formation and metastasis in mouse models of melanoma, pancreatic cancer and triple‑negative breast cancer. Published in Cell Reports Medicine, the study found protection rates up to 88% in some models and reductions in metastatic spread. Lead author Prabhani Atukorale described engineering nanoparticles that activate multiple innate immune pathways simultaneously to provide the co‑stimulatory signals needed for robust T and B cell priming. The approach overcomes formulation incompatibilities among potent adjuvants by integrating them into a single nanoparticle platform. These preclinical results position the platform as a versatile vaccination strategy across tumor types; next steps will focus on safety, antigen selection for humans, and scaling manufacturing for translational studies.